Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Drugs Ethical Standards

 
 
Drug promotion can significantly influence the way medicines are prescribed, dispensed and used. It can lead to over-prescribing and poor quality  prescribing and medicine use which, in turn, can lead to increased risks of adverse effects and higher health-care costs. The World Health Organization established the Ethical Criteria for Medicinal Drug Promotion which defines promotion as "all informational and persuasive activities of manufacturers and distributors that affect the prescription, supply, purchase and/or use of medicinal drugs".
The Lebanese Ministry of Public Health worked on adapting these criteria to national circumstances with the help of all relevant stakeholders under the leadership of Dr. Walid Ammar- General Director of the ministry to have a comprehensive code of ethics to prevent the provision of inaccurate and misleading information and promote the rational use of medicines.
The code of ethics provides guidance for health professionals on how to manage their interactions with industry and guidance for industry about how to implement their marketing practices to establish transparency and accountability in pharmaceutical promotion.
The code is now ready to be launched after it was finalized as a result of a wide participatory process that lasted for 2 years with all relevant stakeholders
 
 

 
    2
ATC Name B/G Ingredients Dosage Form Price
M03AX01 XEOMIN BioTech Clostridium botulinum type A neurotoxin complex - 100 units LD50 100 units LD50 Injectable powder for solution 20,517,541 L.L
M03AX01 XEOMIN BioTech Clostridium botulinum type A neurotoxin complex - 50 units LD50 50 units LD50 Injectable powder for solution 11,920,109 L.L
R03DX05 XOLAIR BioTech Omalizumab - 150mg 150mg Injectable lyophilised powder for solution+diluent 54,613,625 L.L
B02BD02 XYNTHA BioTech Moroctocog alfa - 500IU 500IU Injectable lyophilised powder for solution+diluent L.L
B02BD02 XYNTHA BioTech Moroctocog alfa - 500IU 500IU Injectable lyophilised powder for solution+diluent 23,067,288 L.L
B02BD02 XYNTHA BioTech Moroctocog alfa - 500IU 500IU Injectable lyophilised powder for solution+diluent L.L
S01ED51 XOLAMOL G Timolol (maleate) - 5mg/ml, Dorzolamide HCl - 20mg/ml Drops solution 678,640 L.L
S01ED51 XALACOM B Timolol (maleate) - 6.8mg/ml, Latanoprost - 50?g/ml Drops solution 510,660 L.L
S01EE01 XALATAN B Latanoprost - 50mcg/ml 50mcg/ml Drops solution 704,173 L.L
S01EE01 XALAPROST G Latanoprost - 0.005% w/v 0.005% w/v Drops solution 421,967 L.L
D07AC13 XEMADERM G Mometasone furoate - 0.1% 0.1% Cream 335,961 L.L
L02BB04 XTANDI B Enzalutamide - 40mg 40mg Capsule, soft 278,248,572 L.L
L01ED01 XALKORI B Crizotinib - 250mg 250mg Capsule 347,644,061 L.L
L01ED01 XALKORI B Crizotinib - 200mg 200mg Capsule 347,644,061 L.L
A08AB01 XENICAL B Orlistat - 120mg 120mg Capsule 4,036,903 L.L
L01ED01 XALKORI B Crizotinib - 250mg 250mg Capsule L.L
J01DD15 XEVANEER G Cefdinir - 300mg 300mg Capsule 1,350,562 L.L
    2
Sitemap
© Copyrights reserved to Ministry of Public Health 2025